A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients.

Trial Profile

A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 02 Oct 2012 Results (n=330) presented at the 37th Congress of the European Society of Medical Oncology.
    • 19 Sep 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 31 Aug 2012 Quality-of-life and efficacy results presented at the 14th World Congress on Pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top